Navigation Links
Neuralstem Updates ALS Clinical Trial Progress
Date:2/10/2011

ROCKVILLE, Md., Feb. 10, 2011 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) updated the progress of its ongoing Phase I human clinical trial of the company's spinal cord stem cells in the treatment of ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease) at Emory University in Atlanta, Georgia. The company announced that, after reviewing the safety data from the first nine patients, the trial's Safety Monitoring Board has unanimously approved moving to the last group of ALS patients in this part of the safety trial. These next three patients, all of whom are ambulatory, will each receive ten injections, bilaterally, in the lumbar spinal cord. After this cohort, the FDA will review the trial data to date before approving it to move into the final cohort of patients, who will receive injections in the cervical region of the spinal cord.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO)

"We are delighted that we've advanced to this final cohort of patients in the first part of the safety trial," commented Dr. Eva Feldman, PhD, MD,  Principal Investigator of the trial and a consultant to Neuralstem. Dr. Feldman is Director of the A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan Health System. "We have been pleased with the smooth progress of the trial thus far, from non-ambulatory to ambulatory patients who have an earlier stage of the disease."

"We are greatly encouraged by the SMB's approval to advance the trial to the final three patients to receive full lumbar injections," said Karl Johe, PhD, Chief Scientific Officer and Chairman of Neuralstem's Board of Directors. "The trial has progressed as expected, and we are deeply indebted to the patients and families who have taken part."

About The Trial

The Phase I trial to evaluate the safety of N
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Neuralstem Receives FDA Orphan Designation for Spinal Cord Stem Cells for Treatment of ALS
2. Neuralstem Receives FDA Approval to Commence Drug Trial for Major Depression
3. Neuralstems Human Stem Cells Integrate into Nervous System of Rats with Animal Model of ALS
4. Neuralstems ALS Trial on Clinical Hold
5. Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology
6. Neuralstem Announces Issuance of Core Technology Patent in Europe
7. K-V Pharmaceutical Company Updates Status of New Drug Application for Gestiva™
8. ISTA Pharmaceuticals Achieves 2010 Revenue and Earnings Guidance; Provides 2011 Financial Guidance and Updates Key Plans
9. Vista Partners Updates Coverage on Pro-Pharmaceuticals, Inc.; Maintains Target Price of $2.10
10. Access Pharmaceuticals Updates MuGard Website With First Patient Testimonial Video
11. Intercell AG Announces Q3 2010 Results and Updates on R&D Progress and Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... July 25, 2014 NOT FOR RELEASE, ... INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO ... REGULATIONS OF SUCH JURISDICTION AbbVie (NYSE: ABBV ) ... 30, 2014. "This was another very strong ... share above our original guidance and announced plans to merge ...
(Date:7/24/2014)...   AcelRx Pharmaceuticals, Inc.  (Nasdaq: ACRX ... and commercialization of innovative therapies for the treatment of ... for Zalviso remains July 27, 2014.  The ... the Food and Drug Administration (FDA) had approved Zalviso.  ... notification to the company from the FDA regarding the ...
(Date:7/24/2014)... , July 24, 2014  Restore Health, ... and compounded pharmaceuticals, announced that it is now ... unique to each individual based upon their particular ... by understanding the interaction between a patient,s genetics ... "We,re very excited to provide this new service ...
Breaking Medicine Technology:AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32AbbVie Reports Second-Quarter 2014 Financial Results 33AbbVie Reports Second-Quarter 2014 Financial Results 34AbbVie Reports Second-Quarter 2014 Financial Results 35AbbVie Reports Second-Quarter 2014 Financial Results 36
... YORK, Sept. 8 ACCESS PHARMACEUTICALS, INC. (OTC ... in products for cancer, supportive care, today announced that the ... Conference in New York City on Tuesday, September 14th at ... floor of the New York Palace Hotel.   ...
... GE Healthcare announced today that results from its ... the September issue of Annals of Neurology . ... agent being developed by GE Healthcare, in the field ... the phase 2 study was to investigate the efficacy ...
Cached Medicine Technology:Access Pharmaceuticals to Present At Rodman & Renshaw Annual Global Investment Conference in New York City 2Access Pharmaceuticals to Present At Rodman & Renshaw Annual Global Investment Conference in New York City 3Updated Phase 2 Data With Flutemetamol Published in Annals of Neurology 2Updated Phase 2 Data With Flutemetamol Published in Annals of Neurology 3
(Date:7/25/2014)... Parkulture is proud to announce that ... Jared “JJ” Woods, will be competing on NBC’s highest ... The show will premiere on local affiliates this coming ... the new Esquire Network on Tuesday, July 29th at ... balancing careers as a professional stuntman for film and ...
(Date:7/25/2014)... 25, 2014 Eye & Vision has ... their office location by expanding a new specialized ocular ... comprehensive visual electro-physiology clinic. , By acquiring specialized Visual ... experience in vision problems, patients with vision loss in ... advantage of the implementation of this specialized vision testing ...
(Date:7/25/2014)... 25, 2014 The report “Canada ... provides company shares and distribution shares data for ... profiles of the key market participants, pipeline products, ... market wherever available. , The data in the ... Rsearcher uses epidemiology and capital equipment-based models to ...
(Date:7/25/2014)... NH, 7/25/14) Researchers at Dartmouth-Hitchcock Norris Cotton Cancer ... system so it recognizes and attacks invading cancer cells. ... accepting everything as normal, even while cancer cells ... discussed in a review article published this week in ... jumpstart the body,s ability to fight tumors. Nanoparticles ...
(Date:7/25/2014)... 2014 The American Brain Tumor Association ... Development Trainer of Distinguished Events, and Corporate and Special ... Cancer Society, will be joining the ABTA in the ... will oversee the roll out of a nationwide brain ... The recently launched volunteer network will provide the Chicago-based ...
Breaking Medicine News(10 mins):Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 2Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 3Health News:Eye & Vision, a Leading Eye Doctor Group in Richardson, Celebrate Milestone and Expand Scope of Specialized Eye Care 2Health News:Eye & Vision, a Leading Eye Doctor Group in Richardson, Celebrate Milestone and Expand Scope of Specialized Eye Care 3Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 2Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 3Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 4Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 5Health News:Scientists test nanoparticle 'alarm clock' to awaken immune systems put to sleep by cancer 2Health News:American Brain Tumor Association Recruits Director to Lead New Volunteer Network 2
... ... most wanted gifts for UK mums this Mother,s Day , ... London, UK (PRWEB) March 4, 2010 -- Voucher codes website Savoo.co.uk ... Boots voucher codes travel and clothing are the top three most desired gifts by ...
... ... Kidney Diseases recommends capsaicin as an effective skin care regimen to help relieve itching associated ... be extremely hot. Now there,s a new skin spray made with the essence of hot ... ...
... ... Weight Loss program. With documented success in other parts of the country, doctors Dan Buchanan ... to Cincinnati. , ... (PRWEB) March 4, 2010 -- UniqueU Medical Weight Loss Program opened in Kenwood, a ...
... ASTHMA HAVE INCREASED HEALTH RISKS , Pregnant women with ... symptoms and fetal growth abnormalities. Researchers from the Medical ... asthma to determine the effect of active and passive ... the women, 418 (18 percent) reported active smoking; among ...
... say they "had sex," what transpired is anyone,s guess. A ... that no uniform consensus existed when a representative sample of ... them. Is oral sex considered sex? It wasn,t ... anal sex? For around 20 percent of the participants, no. ...
... ... ... ... ...
Cached Medicine News:Health News:Voucher Site Savoo.co.uk Reveals What Mum's Really Want This Mother's Day 2Health News:Hot Pepper Itch Remedy Targets Kidney Disease Patients Suffering From Chronic Pruritus 2Health News:UniqueU Medical Weight Loss Program Opens Cincinnati Location 2Health News:News briefs from the March issue of Chest 2Health News:IU study finds no consensus in definitions of 'had sex' 2Health News:IU study finds no consensus in definitions of 'had sex' 3Health News:UMDNJ Online Graduate Certificate in Aging Program Accepting Applications 2Health News:UMDNJ Online Graduate Certificate in Aging Program Accepting Applications 3Health News:UMDNJ Online Graduate Certificate in Aging Program Accepting Applications 4Health News:UMDNJ Online Graduate Certificate in Aging Program Accepting Applications 5Health News:UMDNJ Online Graduate Certificate in Aging Program Accepting Applications 6
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: